PI3K pathway protein analyses in metastatic breast cancer patients receiving standard everolimus and exemestane.

CONCLUSIONS: IHC of single proteins or heatmap subgroups of the differentially activated PI3K/MAPK pathways was not able to discriminate patients on EVE/EXE with poor or better PFS. Upregulation of p-4EBP1 in pre-treatment biopsies as compared to levels in primary tumours pointed towards shorter PFS.
PMID: 32566979 [PubMed - indexed for MEDLINE]

Source: Clinical Genitourinary Cancer - October 8, 2020 Category: Cancer & Oncology Authors: Kruger DT, Opdam M, van der Noort V, Sanders J, Nieuwenhuis M, de Valk B, Beelen KJ, Linn SC, Boven E Tags: J Cancer Res Clin Oncol Source Type: research